Ambu A/S
CSE:AMBU B
Net Margin
Ambu A/S
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| DK |
|
Ambu A/S
CSE:AMBU B
|
25.3B DKK |
6%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
230.4B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
172.9B USD |
29%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
156.1B USD |
14%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
150.3B USD |
12%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
120.1B USD |
14%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
54B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
57B USD |
8%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
51B USD |
24%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.4B USD |
73%
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
42.4B USD |
27%
|
Ambu A/S
Glance View
Ambu A/S, a Danish company rooted in innovation, has carved a niche in the global healthcare sector through its specialized medical devices. Founded in 1937, Ambu started with a simple mission of improving patient care and has stayed true to that vision by continuously advancing their portfolio. The company's journey began with the invention of the resuscitator bag, a revolutionary product that remains a staple in emergency and hospital settings today. Over the years, Ambu has focused strategically on three main segments: Anesthesia, Patient Monitoring & Diagnostics, and Visualisation, each playing a crucial role in the broader healthcare ecosystem. These segments allow Ambu to develop devices that enhance diagnostic procedures, improve safety, and increase efficiency in medical settings, ultimately saving lives and optimizing healthcare delivery. Ambu’s business model capitalizes primarily on innovation-driven sales, with a strong emphasis on disposable medical devices which are gaining popularity due to hygiene concerns and regulatory trends favoring single-use technologies. These products include their flagship single-use endoscopes, marketed under the brand name "Ambu aScope," which significantly reduce the risk of cross-contamination while providing high-quality diagnostic images. The company's revenue model is built on a B2B approach, dealing directly with hospitals, clinics, and other healthcare providers, ensuring a steady flow of sales through long-term contracts and partnerships. Through constant reinvestment into R&D and strategic acquisitions, Ambu sustains its market leadership, driving growth by addressing the evolving needs of the healthcare industry and setting standards in patient care solutions globally.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Ambu A/S's most recent financial statements, the company has Net Margin of 6.3%.
You don't have any saved screeners yet